Evaluation of procalcitonin-guided antimicrobial stewardship in patients admitted to hospital with COVID-19 pneumonia

Maria Calderon1†, Ang Li1*,†, Juan Carlos Bazo-Alvarez2,3, Jonathan Dennis1, Kenneth F. Baker4,5, Ina Schim van der Loeff6, Aidan T. Hanrath1, Richard Capstick1, Brendan A. I. Payne1,6, Daniel Weiand6, Ewan Hunter1 and Ulrich Schwab1

1Department of Infection and Tropical Medicine, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK; 2Research Department of Primary Care & Population Health, University College London, London, UK; 3Escuela de Medicina, Universidad Cesar Vallejo, Trujillo, Peru; 4Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 5NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 6Microbiology Department, Integrated Laboratory Medicine Directorate, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

*Corresponding author. E-mail: ang.li1@nhs.net
†These authors contributed equally to this article as first authors.

Received 8 April 2021; accepted 21 July 2021

Background: Procalcitonin is a biomarker that may be able to identify patients with COVID-19 pneumonia who do not require antimicrobials for bacterial respiratory tract co-infections.

Objectives: To evaluate the safety and effectiveness of a procalcitonin-guided algorithm in rationalizing empirical antimicrobial prescriptions in non-critically ill patients with COVID-19 pneumonia.

Methods: Retrospective, single-site, cohort study in adults hospitalized with confirmed or suspected COVID-19 pneumonia and receiving empirical antimicrobials for potential bacterial respiratory tract co-infection. Regression models were used to compare the following outcomes in patients with and without procalcitonin testing within 72 h of starting antimicrobials: antimicrobial consumption (DDD); antimicrobial duration; a composite safety outcome of death, admission to HDU/ICU or readmission to hospital within 30 days; and length of admission. Procalcitonin levels of \( \leq 0.25 \text{ ng/L} \) were interpreted as negatively predictive of bacterial co-infection. Effects were expressed as ratios of means (ROM) or prevalence ratios (PR) accordingly.

Results: 259 patients were included in the final analysis. Antimicrobial use was lower in patients who had procalcitonin measured within 72 h of starting antimicrobials: mean antimicrobial duration 4.4 versus 5.4 days, adjusted ROM 0.7 (95% CI 0.6–0.9); mean antimicrobial consumption 6.8 versus 8.4 DDD, adjusted ROM 0.7 (95% CI 0.6–0.8). Both groups had similar composite safety outcomes (adjusted PR 0.9; 95% CI 0.6–1.3) and lengths of admission (adjusted ROM 1.3; 95% CI 0.9–1.6).

Conclusions: A procalcitonin-guided algorithm may allow for the safe reduction of antimicrobial usage in hospitalized non-critically ill patients with COVID-19 pneumonia.

Introduction

It can be difficult to confidently distinguish COVID-19 pneumonia from bacterial pneumonia, owing to similarities in clinical presentation and frequently raised inflammatory markers including C-reactive protein.1–3 Furthermore, there are few data on how frequently bacterial co-infection occurs in patients with COVID-19. Although a large proportion of patients admitted to hospital with COVID-19 pneumonia receive antimicrobials [83% overall, 93% of patients admitted to a high dependency unit (HDU) or ICU],2,4 rates of confirmed bacterial co-infection are low (6.9% overall, 8.1% in critically unwell patients5,6), suggesting that antimicrobials are not necessary for most patients. Judicious use of antimicrobials is an important element of efforts to limit rising antimicrobial resistance worldwide,7 and the widespread use of antimicrobials for COVID-19 pneumonia is therefore of concern.8 Biomarkers or decision-aids that can assist clinicians in distinguishing COVID-19 pneumonia from bacterial community-acquired pneumonia (CAP) are therefore needed. Previous publications have postulated procalcitonin as a possible useful aid for...
antimicrobial stewardship in COVID-19 pneumonia, especially in light of the indiscriminate antimicrobial usage.9-11

Procalcitonin is a protein precursor of calcitonin that is present in low levels in healthy individuals.12 It is modulated by IL-1β, TNF-α, IL-2 and IL-6, and while levels rise in infection in general, the response to cytokines involved in viral infection is less marked.13,14 Procalcitonin-based protocols for limiting antimicrobial use for acute respiratory tract infections have been evaluated in a Cochrane systematic review.15 This showed statistically significant reductions in antimicrobial exposure and antimicrobial-associated side effects compared with standard care, with no differences in rates of treatment failure.

In the present study, we evaluated the effectiveness and safety of a procalcitonin-guided antimicrobial decision-aid in non-critically ill patients with COVID-19 pneumonia.

Patients and methods

Ethics

This project was conducted in accordance with the Declaration of Helsinki and national and institutional standards. As a retrospective service evaluation, formal ethical approval was not required. Patient consent was not required as a study of COVID-19 in accordance with Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002.16 Approval for relevant patient-identifiable information to be used was granted by the Newcastle upon Tyne Hospitals (NUTH) Caldicott Guardian.

Study design and setting

We conducted a retrospective, single-site cohort study to evaluate the clinical effectiveness and safety of a procalcitonin-guided protocol on the use of empirical antimicrobials in patients admitted to the NUTH NHS Foundation Trust, UK, with confirmed or suspected COVID-19 pneumonia. NUTH provides secondary and tertiary care across two hospital sites with over 1800 inpatient beds. It is also one of five centres in England designated for the management of airborne high consequence infectious diseases.17 Procalcitonin assays were not routinely performed at NUTH prior to the COVID-19 pandemic and were introduced as part of the emergency response.

We report our findings using the recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative18 (see Section 1 of the Supplementary data at JAC Online).

Inclusion and exclusion criteria

Patients admitted to NUTH with laboratory-confirmed or clinically suspected COVID-19 pneumonia between 12/03/2020 and 01/07/2020 were identified through clinical coding and laboratory record searches. These dates encompass the period immediately following the formal end of the ‘contain’ phase of the UK pandemic response, capturing the first wave of the UK epidemic.19 Cases of COVID-19 pneumonia were defined as patients with clinical or radiological evidence of pneumonia and either a positive SARS-CoV-2 PCR swab taken during admission, or an admission episode with ICD-10 code U07.2.20 This code encompasses cases that have been diagnosed on clinical or epidemiological grounds but in which the virus has not been detected.

Electronic case notes including observations, investigation results and prescription records were reviewed. Patients were excluded for any of the following reasons: being younger than 18 years; being admitted to the HDU or ICU within 72 h of admission; not receiving antimicrobials during their admission; indication for antimicrobial treatment other than respiratory tract infection; antimicrobials being stopped as part of treatment rationalization in end-of-life care. A sensitivity analysis that included this final group of patients was performed to reflect real-world practice, exploring whether exclusion of these patients led to a change in the overall findings.

Included patients were grouped for comparison according to whether or not procalcitonin was measured within 72 h after antimicrobial initiation. The upper limit of 72 h was chosen in line with Public Health England’s ‘Start Smart—Then Focus’ antimicrobial stewardship toolkit.21

The following data were collected for all included patients: demographics; comorbidities of cardiovascular disease, respiratory disease, diabetes and obesity; duration of symptoms prior to admission; symptoms of cough, shortness of breath, fever and gastrointestinal symptoms; vital sign observations; and radiological findings on admission. Prescribing data on antimicrobial indication, dose, route, and duration were collected; any antimicrobials continued after discharge were assumed to have been completed as prescribed. If patients participated in open label clinical trials and were randomized to receive antimicrobials as an investigational product, these treatments were not included in estimates of antimicrobial exposure or consumption. Any other antimicrobials received by these patients for respiratory tract infection were included in the analysis. Any available results from culture of respiratory and/or blood samples were also reviewed and collated.

Procalcitonin assay

The Cobas Elecsys BRAHMS Procalcitonin immunoassay was introduced on 30 March 2020 for quantitative determination of procalcitonin;22 serum for this assay was collected in standard BD vacutainer SST II™ Advance tubes. Introduction of the assay was accompanied by dissemination of clinical guidance containing an institutional algorithm describing interpretation of procalcitonin results. This recommended that empirical antimicrobial treatment for respiratory tract infection could be stopped in patients with proven or suspected SARS-CoV-2 infection who had a procalcitonin level of ≤0.25 ng/mL. This cut-off was chosen to correspond with a conservative approach in a ‘moderate risk/acuity’ group of hospitalized patients.23 Results were not interpreted in isolation but rather as an adjunct to overall clinical judgement. A summary of the guidance is provided as Supplementary data (Section 2).

Outcome measures

Primary outcome measures were duration of antimicrobial exposure and per-patient antimicrobial consumption. Duration of exposure was calculated as the time from first to last dose plus the prescribed dosing interval. Per-patient consumption was calculated by applying the current World Health Organisation Defined Daily Dose (DDD) method.24

To assess safety, we used a composite outcome comprising death, admission to HDU/ICU >72 h after starting antimicrobial...
treatment, or readmission to hospital within 30 days. Deaths in the community after discharge from hospital were also captured through robust daily electronic system record updates via primary care.

**Data analysis**

Sample size was calculated based on the results of a systematic review by Schuetz et al.\(^{15}\) that evaluated procalcitonin-guided antimicrobial stewardship algorithms in patients with acute respiratory tract infections. To detect a similar reduction in antimicrobial exposure of 2.4 days (95% CI 2.15–2.71) with 80% power and 95% confidence would require at least 116 patients in each comparison group.\(^{25}\)

Primary outcomes between the procalcitonin and non-procalcitonin groups were compared using ratios of means (ROM) and prevalence ratios (PR). ROMs were estimated for continuous outcomes by fitting generalized linear models (GLMs) with a
Dichotomous outcomes were compared using PR, which were estimated by fitting robust Poisson models. Adjusted estimates controlled for clinically plausible confounding variables identified in the univariate analysis and not found to possess collinearity with other confounders. Analyses with details of the models and confounders are detailed in Supplementary data (Section 3).

A time series analysis was performed to visualize antimicrobial consumption over time in both groups. Daily antimicrobial consumption by all patients included in the main analysis was aggregated; independent time series were then modelled for each group by fitting a GLM (Gaussian distribution, link identity), treating antimicrobial consumption as a continuous outcome and date of admission as a predictor. All models were adjusted for autocorrelation and seasonality using Fourier terms.

Reflecting the real-world effect of the availability and use of the procalcitonin assay, a sensitivity analysis was performed by re-including in both groups patients who had discontinued antimicrobials due to palliation at the end of life. Sensitivity analyses were performed for both the primary outcomes and time series analysis; a

| Table 1. Main characteristics of the population |
|-----------------------------------------------|
| Characteristic | Non-procalcitonin (N = 142) | Procalcitonin (N = 117) |
|----------------|-------------------------------|-------------------------|
| Age, years, mean (SD) | 73.6 (+14.5) | 67.7 (+17.0) |
| Age group, years, n (%) | | |
| 18–39 | 5 (3.5) | 8 (6.8) |
| 40–49 | 6 (4.2) | 11 (9.4) |
| 50–59 | 14 (9.9) | 18 (15.4) |
| 60–69 | 15 (10.6) | 27 (23.1) |
| 70–79 | 46 (32.4) | 18 (15.4) |
| >80 | 56 (39.4) | 35 (29.9) |
| Sex, n (%) | | |
| Female | 70 (49.3) | 56 (47.8) |
| Comorbidities, n (%) | | |
| Any cardiovascular disease | 83 (58.5) | 59 (50.4) |
| Respiratory condition | 46 (33.4) | 46 (39.3) |
| Obesity | 15 (10.6) | 21 (17.9) |
| Diabetes (Type 1 or 2) | 24 (16.9) | 30 (25.6) |
| Number of comorbidities, n (%) | | |
| No comorbidities | 12 (8.5) | 11 (9.4) |
| 1 to 2 comorbidities | 38 (26.7) | 27 (23.1) |
| More than 2 comorbidities | 92 (64.8) | 79 (67.5) |
| Clinical markers of severity | | |
| Symptoms at admission, n (%) | | |
| Fever | 58 (40.9) | 72 (61.5) |
| Cough | 68 (47.9) | 77 (65.8) |
| Shortness of breath | 81 (57.0) | 80 (68.4) |
| Gastrointestinal symptoms | 11 (7.6) | 18 (15.4) |
| Signs at admission, n (%) | | |
| Fever (≥37.5°C) | 49 (34.5) | 48 (41.0) |
| Tachypnoea (>20 breaths/min) | 72 (50.7) | 79 (67.5) |
| Oxygen supplementation | 59 (41.5) | 67 (57.3) |
| NIV (on admission) | 0 (0) | 0 (0) |
| Time from onset of symptoms to admission, days, median (IQR) | 5 (2–10) | 3 (2–9) |
| Radiological changes at admission, n (%) | 93 (65.5) | 87 (74.4) |
| PCR-confirmed COVID-19, n (%) | 120 (84.5) | 79 (67.5) |
| Procalcitonin levels, ng/mL, median (IQR) | | 0.2 (0.1–0.4) |
| Procalcitonin group, ng/mL, n (%) | | |
| ≤0.25 | – | 73 (62.4) |
| 0.26–0.5 | – | 17 (14.5) |
| 0.6–1.0 | – | 14 (12.0) |
| >1.0 | – | 13 (11.1) |

NIV, non-invasive ventilation.

aVariables with statistical evidence of association that were included in the final model (P < 0.05). Definitions of the variables included are described in Supplementary Material 3.

logarithmic link and assuming a gamma distribution (γGLM). Dichotomous outcomes were compared using PR, which were estimated by fitting robust Poisson models. Adjusted estimates controlled for clinically plausible confounding variables identified in the univariate analysis and not found to possess collinearity with other confounders. Analyses with details of the models and confounders are detailed in Supplementary data (Section 3).
Table 2. Summary of outcome measures and estimates of effect

| Characteristic              | Non-procalciton (N = 142) | Procalciton (N = 117) | Unadjusted | Adjusted $^b$ |
|----------------------------|---------------------------|-----------------------|------------|--------------|
| Continuous measures        |                           |                       | ROM (95% CI) | ROM (95% CI) |
| Duration of antibiotics (days) | 5.4 (2.8)                | 4.4 (3.1)             | 0.8 (0.7–0.9) | 0.7 (0.6–0.9) |
| Consumption of antibiotic (DDD) | 8.4 (5.7)                | 6.8 (5.6)             | 0.8 (0.7–0.9) | 0.7 (0.6–0.8) |
| Length of stay (days)      | 9.1 (8.5)                 | 9.8 (7.4)             | 1.1 (0.9–1.3) | 1.3 (0.9–1.6) |
| Categorical measures       |                           |                       | PR (95% CI)  | PR (95% CI)  |
| Composite safety outcome$^a$ | 40 (28.1)                 | 26 (22.2)             | 0.8 (0.6–1.2) | 0.9 (0.6–1.3) |
| 30 day mortality           | 27 (19.0)                 | 8 (6.9)               | 0.5 (0.3–0.9) | 0.6 (0.4–1.1) |

ROM, ratio of means; PR, prevalence ratio; DDD, defined daily doses.

$a$ Full details of modelling and variables are included in Supplementary Materials.

$b$ Adjusted for age, sex, comorbidities, COVID-19 status, and fever, cough, respiratory rate and oxygen requirement at time of admission.

$c$ This measure comprises death during admission, not being alive at 30 days from admission, readmission during study period, and/or admission to ICU.

There were no differences in the composite safety outcome in both unadjusted and adjusted analyses. Analysis of mortality in isolation showed a non-statistically significant trend towards patients in the procalcitonin group being less likely to die within 30 days (adjusted PR = 0.6; 95% CI: 0.4–1.1; Table 2).

Time series analysis of the mean patient antimicrobial consumption showed a decreasing trajectory over time in the procalcitonin group ($\beta_{slope} = -0.07$, 95% CI: $-0.11$ to $-0.03$), with negligible change seen in the non-procalcitonin group ($\beta_{slope} = -0.01$, 95% CI: $-0.05$ to 0.02) (Figure 2a). Sensitivity analysis, after inclusion of those patients where antimicrobials were discontinued as part of end-of-life care, demonstrated similar findings (procalcitonin group: $\beta_{slope} = -0.06$, 95% CI: $-0.10$ to $-0.02$; non-procalcitonin group: $\beta_{slope} = -0.01$, 95% CI: $-0.05$ to 0.02) (Figure 2b). Although mean consumption was initially higher in the procalcitonin group, there was crossover in both primary and sensitivity analyses at between 1 and 2 months after assay introduction.

Discussion

To our knowledge, this is the first study to evaluate the clinical impact and safety of early procalcitonin-guided antimicrobial stewardship in patients with COVID-19 pneumonia in comparison with a standard of care not including routine procalcitonin assays. Prior studies have been conducted within cohorts where all patients underwent procalcitonin testing, or have focused on the role of procalcitonin as a biomarker of disease severity and prognosis. We found a moderate reduction in antimicrobial duration and consumption in patients where procalcitonin was measured within 72 h of starting antimicrobials, with no differences in adverse outcomes or length of stay. Our results suggest that it is safe to use a procalcitonin-based protocol in the antimicrobial decision-making process. It is important to note that our algorithm used a cut-off of $\leq 0.25$ ng/L as being negatively predictive of bacterial co-infection, and the potential impact of using higher or lower thresholds.
warrants evaluation in larger, ideally prospective, studies. Microbiological results from sputum and blood cultures are in keeping with the low frequency of isolates seen in comparable settings. A major advantage of the procalcitonin assay is that it can be rapidly performed using a readily obtainable blood sample, in contrast to respiratory tract cultures which are limited by challenges in sample collection and minimum growth times. However, clinical situations that increase the potential for false-negative procalcitonin results, including localized infections such as empyema, atypical infections, patients receiving renal replacement therapy, and if measured too early or too late in the course of infection. These and other factors mandate the interpretation of procalcitonin levels within the context of other laboratory and clinical findings.

Figure 2. Time series analysis of antimicrobial consumption (DDD) over time. (a) Main analysis. (b) Sensitivity analysis including end-of-life patients. Observation was considered from 28 March 2020, this was the earliest date of admission where patients fulfilled the inclusion criteria of procalcitonin measurement within 72 h of starting antimicrobials.
diverging from consumption in the non-procalcitonin group at just over a month following introduction of the assay. We hypothesize that this may be explained by a relative lack of prior institutional experience with procalcitonin, with an initial period of adoption into practice at least partly accounting for this trend.

Our study has some important strengths. The number of patients within the comparison groups exceeded our pre hoc sample size calculation for comparison of antimicrobial durations. We also suggest that our safety outcome was robust, as we included all deaths within 30 days of starting antimicrobials, including community deaths following discharge from hospital.

There are also limitations that warrant discussion. While the WHO DDD method provides a standardized framework to measure antimicrobial consumption, there are limitations to this method in respect to antimicrobial stewardship goals. These include assigning equivalent importance to all classes, with no weighting applied to broad- versus narrow-spectrum agents. Furthermore, DDD does not account for dose adjustments in patients with low renal function or low body weight. Although an interrupted time series analysis was possible, the brevity of the period prior to introduction of the procalcitonin assay precludes drawing any firm inferences due to limited numbers of patients admitted with COVID-19 pneumonia. It is possible, however, to see trends over time that give an informative picture of changes that occurred after the assay was introduced. Another limitation of time series analyses is their inability to adjust for potential confounders, although the overall results are concordant with the yGLM-adjusted effect estimate for antimicrobial consumption. A description of socio-economic risk factors for adverse COVID-19 outcomes, as identified by Public Health England, would have added interest to our discussion. Our system does not routinely collect information on factors such as multiple deprivation index and these were therefore not available for this analysis. We did consider constructing a proxy socioeconomic variable derived from area of residence, although this method is better suited to much larger cohort or ecological studies that are able to provide greater statistical power, and we decided that this approach would not be valid in a relatively small retrospective clinical study such as ours.

Finally, the retrospective design may have introduced biases, thereby limiting inferences and extrapolation from our results. Selection bias is an important limitation inherent to observational studies like ours. For example, clinicians may have limited their use of the procalcitonin assay in patients in whom the presence of bacterial infection seemed less likely, such as those without clear clinical signs and symptoms suggestive of bacterial pneumonia. It is therefore possible that there are different a priori risks for the safety outcomes between the comparison groups. Similarly, the higher crude 30 day mortality rate within the non-procalcitonin group may be due to such differences, especially the unequal distribution of ages, a well-defined risk factor for mortality, between the groups. It was therefore unsurprising that there was no difference in 30 day mortality following adjustment for confounding.

We recognize that the care of patients with COVID-19 pneumonia has evolved over the course of the pandemic. For example, greater emphasis on non-invasive respiratory support with high flow nasal cannula or continuous positive airway pressure ventilation has meant that patients who previously required early transfer to HDU/ICU may now be cared for in specialized medical wards. Additionally, the majority of the patient cohort were admitted prior to the routine use of dexamethasone (22 June 2020) and remdesivir (5 June 2020) for patients with COVID-19 in the UK, potentially impacting the extrapolation of the mortality and safety outcomes that we found. Our study does not specifically identify patients who required early initiation of respiratory support, and the results should be interpreted with this in mind. We also excluded patients requiring early admission to HDU/ICU as we considered the clinical and microbiological risk factors in this group to be sufficiently different as to require independent study. Other groups have reported on the use of procalcitonin within this cohort of patients, demonstrating fewer days of antimicrobial use in patients with procalcitonin levels of <0.5 ng/mL.

Finally, while our results support early procalcitonin testing as an antimicrobial stewardship tool, the economic implications of more widespread use also need to be considered. Given that the average cost of procalcitonin is £13.79 per test, evaluation of the cost-effectiveness of a procalcitonin-guided approach alongside other antimicrobial stewardship methods is required.

In conclusion, we observed that patients who underwent early procalcitonin measurement (within 72 h), supported by an algorithm to aid interpretation, had reduced empirical antimicrobial usage with no adverse effect on safety. Our finding supports the use and further investigation of procalcitonin as an antimicrobial stewardship tool for non-critically ill patients admitted with suspected or laboratory-confirmed COVID-19 pneumonia.

Acknowledgements
The authors would like to thank John Hardy and Jessica McCutcheon of the Blood Sciences department of the Integrated Laboratory Medicine directorate for their work in the local verification and ongoing provision of the procalcitonin assay. We are also grateful to Neil Alderson and Holly Robinson of the Information Management and Technology Directorate for their assistance with the medical record and clinical coding searches. We also acknowledge the help of the following medical staff who assisted with clinical data collection: Su Ann Tee, Gabriella Marchitelli, Andrew Barr, Alsafi Eid, Sajeeel Ahmed, Dalvir Bajwa and Omar Mohammed.

Funding
This study was conducted as part of our routine work. K.F.B. is funded by a National Institute for Health Research (NIHR) Clinical Lectureship (CL-2017-01-004). B.A.I.P. is funded by Wellcome (109975/Z/15/Z, 203105/Z/16/Z). The funders had no role in study design; data collection, analyses or interpretation; manuscript writing; or in the decision to publish the results.

Transparency declarations
None to declare.

Author contributions
U.S., E.H., D.W. contributed to the conception and design of the study and interpretation of data. A.L., M.C., J.D., K.F.B., I.S.v.d.L., A.T.H. and R.C. contributed to the data collection. J.C.B.-A., M.C., A.L., B.A.I.P. contributed...
to the analysis. A.L., M.C. contributed to the original drafting of the article. All authors critically reviewed the work for intellectual content and interpretation of data; all authors approved the final version of the text.

Disclaimer
The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Supplementary data
Sections 1 to 3 and Tables S1 and S2 are available as Supplementary data at JAC Online.

References
1. Zhang G, Hu C, Luo L et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 2020; 127: 104-364.
2. Pritchard M, Dankwa EA, Hall M et al. ISARIC Clinical Data Report 4 October 2020. medRxiv. 2020. http://medrxiv.org/content/early/2020/10/06/2020.17.20155218.abstract.
3. Zhang JQ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75: 1730–41.
4. ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium). COVID-19 Report 2020. https://isaric.ghrtn.org.
5. Langford BJ, So M, Raybahran S et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26: 1622–9.
6. Rawson TM, Moore LSP, Zhu N et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71: 2459–68.
7. Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck. Infect Control Hosp Epidemiol 2020; 41: 744–5.
8. Lynch C, Mahida Y, Gray J. Antimicrobial stewardship: a COVID casualty? J Hosp Infect 2020; 106: 401–3.
9. van Duin D, Barlow G, Nathwani D. The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. JAC Antimicrob Resist 2020; 2: diao053.
10. Falcone M, Tiseo G, Giordano C et al. Bacterial infection in patients with COVID-19: a living rapid review and meta-analysis. J Glob Antimicrob Resist 2020; 22: 782–4.
11. Martin E, Phiblin M, Hughes G et al. Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic. J Antimicrob Chemother 2021; 76: 272–75.
12. Dandonna P, Nix D, Wilson MF et al. Procalcitonin increase after endotopic injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605–8.
13. Oberhoffer M, Stonan S, Russwurm S et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134: 49–55.
14. Jin M, Khan AI. Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. Lab Med 2010; 41: 173–7.
15. Schuetz P, Witz Y, Sager R et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; issue 10: Cd007498.
16. United Kingdom: Department of Health and Social Care. Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 – general. 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information/coronavirus-covid-19-notice-under-regulation-34-of-the-health-service-control-of-patient-information-regulations-2002-general-2.
17. Lilie PJ, Samson A, Li A et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. J Infect 2020; 80: 578–606.
18. Vandernbroecke JP, van Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18: 805–35.
19. UK Government. COVID-19: government announces moving out of contain phase and into delay. 2020. https://www.gov.uk/government/news/covid-19-government-announces-moving-out-of-contain-phase-and-into-delay.
20. WHO. Emergency use ICD codes for COVID-19 disease outbreak. 2020. https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak.
21. Public Health England. Antimicrobial stewardship: Start smart - then focus. 2020. https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus.
22. National Institute for Health and Care Excellence (NICE). Procalcitonin testing for diagnosing and monitoring sepsis (ADIVA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). 2018. https://www.nice.org.uk/guidance/dg18/resources/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-arrays-brahms-pct-sen-sitive-kryptor-assay-elecsys-brahms-pct-assay-liasion-brahms-pct-arrays-and-vidas-brahms-pct-arrays-pdf-1053636508357.
23. Schuetz P, Chiappa V, Briel M et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171: 1322–31.
24. WHO. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment. 2019. https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/.
25. Rosner B. Hypothesis testing; two-sample inference - estimation of sample size and power for comparing two means. In: Fundamentals of Biostatistics. Cengage Learning, 2016; 307–15.
26. Williamson EJ, Walker AJ, Bhaskaran K et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–6.
27. Heesom L, Rehnberg L, Nasim-Mohi M et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist 2020; 22: 782–4.
28. Lippi G, Piebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020; 505: 190–1.
29. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27: 83–8.
30. Sepulveda J, Westblade LF, Whittier S et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol 2020; 58: e00875-20.
31. Schuetz P, Bretscher C, Bernasconi L et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev Mol Diagn 2017; 17: 593–601.
32. Christ-Crain M, Muller B. Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Med Wkly 2005; 135: 451–60.
33. Public Health England. Research and analysis COVID-19: review of disparities in risks and outcomes. 2020. https://www.gov.uk/government/publications/covid-19-review-of-disparities-in-risks-and-outcomes.
34. O’Driscoll M, Ribeiro Dos Santos G, Wang L et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021; 590: 140–5.
35 Burns GP, Lane ND, Tedd HM et al. Improved survival following ward-based non-invasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: retrospective analysis from a UK teaching hospital. BMJ Open Respir Res 2020; 7: e000621.

36 National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19. 2021. https://www.nice.org.uk/advice/es27/chapter/Key-messages.

37 National Institute for Clinical Excellence. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). 2015. https://www.nice.org.uk/guidance/dg18/.